Latest News about Weight Loss
Recent news which mentions Weight Loss
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
November 21, 2024
From Benzinga
From Benzinga
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
September 25, 2024
Tickers
LLY
From Benzinga
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
September 25, 2024
Tickers
NVO
From Benzinga
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
September 25, 2024
From Benzinga
Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO
September 24, 2024
Tickers
NVO
From Benzinga
Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints
September 20, 2024
From Benzinga
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
September 20, 2024
From Benzinga
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
September 11, 2024
Tickers
VKTX
From Benzinga
September Volatility Returns As Labor Cools, Bets On Large Fed Rate Cut Intensify, Semiconductors Plunge: This Week In The Markets
September 06, 2024
From Benzinga
From Benzinga
Hims & Hers Health Sees Major Growth Opportunity In Booming Weight Loss Market, Says Analyst
August 22, 2024
From Benzinga
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
August 21, 2024
From Benzinga
Weight-Loss Giant Novo Nordisk Tumbles To 200-Day Average Support: 'Weakness Could Be Buying Opportunity,' Analyst Says
August 07, 2024
Tickers
NVO
From Benzinga
What's Going On With HIMS Shares Today?
August 01, 2024
From Benzinga
From Benzinga
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
July 09, 2024
From Benzinga
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
July 07, 2024
From Benzinga
From PRLog
From Benzinga
From Benzinga
From Benzinga
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
June 21, 2024
From Benzinga
JPMorgan's $500M Venture Capital Fund Bets Big On Weight-Loss Drugs: 'They're All The Rage'
June 13, 2024
From Benzinga
From Benzinga
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
June 07, 2024
From Benzinga
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
June 05, 2024
From Benzinga
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
More ways to get to us
Facebook
Twitter
YouTubeContact the Lethbridge Herald
504 - 7th Street South
Lethbridge, AB T1J 3Z7
[P] (403) 328-4411
[F] (403)328-4536
Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.